An arrhythmogenic metabolite in atrial fibrillation.
Julia KrauseAlexander NickelAlexandra MadsenHamish M Aitken-BuckA M Stella StoterJessica SchrapersFrancisco OjedaKira GeigerMelanie KernMichael KohlhaasEdoardo BerteroPatrick HofmockelFlorian HübnerInes AssumMatthias HeinigChristian MüllerArne HansenTobias KrauseDeung-Dae ParkSteffen JustDylan AïssiDaniela BörnigenDiana LindnerNele FriedrichKhaled AlhussiniConstanze BeningRenate B SchnabelMahir KarakasLicia IacovielloVeikko SalomaaAllan LinnebergHugh Tunstall-PedoeKari KuulasmaaPaulus KirchhofStefan BlankenbergTorsten ChristThomas EschenhagenRegis R LambertsChristoph MaackJustus StenzigTanja ZellerPublished in: Journal of translational medicine (2023)
Our data provide evidence for an arrhythmogenic potential of the metabolite C18:1AC. The metabolite interferes with mitochondrial metabolism, thereby contributing to contractile dysfunction and shows predictive potential as novel circulating biomarker for risk of AF.
Keyphrases
- atrial fibrillation
- oxidative stress
- heart failure
- left atrial
- skeletal muscle
- oral anticoagulants
- human health
- left atrial appendage
- catheter ablation
- electronic health record
- direct oral anticoagulants
- big data
- percutaneous coronary intervention
- acute coronary syndrome
- climate change
- left ventricular
- artificial intelligence
- data analysis